## Joanne Langley

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8746512/publications.pdf

Version: 2024-02-01

47409 68831 8,032 187 49 81 citations h-index g-index papers 198 198 198 9132 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine, 2022, 40, 450-458.	1.7	10
2	Infected branchial cleft cyst in a newborn. Journal of Pediatric Surgery Case Reports, 2022, , 102275.	0.1	O
3	The palivizumab patchwork: Variation in guidelines for Respiratory Syncytial Virus prevention across Canadian provinces and territories. Paediatrics and Child Health, 2021, 26, e115-e120.	0.3	5
4	The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clinical Infectious Diseases, 2021, 73, 2257-2264.	2.9	376
5	Potential resurgence of respiratory syncytial virus in Canada. Cmaj, 2021, 193, E1140-E1141.	0.9	24
6	Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada. Preventive Medicine, 2021, 148, 106564.	1.6	40
7	A palpable chest wall mass in a 4-year-old boy. Jammi, 2021, 6, 236-240.	0.3	O
8	Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada. EClinicalMedicine, 2021, 41, 101141.	3.2	14
9	Mechanical complications of central venous catheters in children: A cohort study. Infection Control and Hospital Epidemiology, 2021, , 1-7.	1.0	3
10	Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. Vaccine, 2020, 38, 1384-1392.	1.7	53
11	Lyme disease in children: Data from the Canadian Paediatric Surveillance Program. Ticks and Tick-borne Diseases, 2020, 11, 101347.	1.1	6
12	The Power of First Impressions: Can Influenza Imprinting during Infancy Inform Vaccine Design?. Vaccines, 2020, 8, 546.	2.1	5
13	A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age. Vaccines, 2020, 8, 393.	2.1	7
14	Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein. Human Vaccines and Immunotherapeutics, 2020, 16, 2007-2017.	1.4	7
15	Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States. Cmaj, 2020, 192, E666-E670.	0.9	65
16	Incorporation of health economic evaluation into immunization policy-making in Canada: Barriers and facilitators. Vaccine, 2020, 38, 2512-2518.	1.7	3
17	Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1. Emerging Infectious Diseases, 2020, 26, 454-462.	2.0	1
18	Birth by Caesarean section and otitis media in childhood: a retrospective cohort study. Scientific Reports, 2020, 10, 5219.	1.6	5

#	Article	IF	Citations
19	Projecting demand for critical care beds during COVID-19 outbreaks in Canada. Cmaj, 2020, 192, E489-E496.	0.9	132
20	Estimations du taux de létalité de la COVID-19 au Canada et aux États-Unis sur une période donnée. Cmaj, 2020, 192, E1482-E1486.	0.9	0
21	Pediatric Investigators Collaborative Network on Infections in Canada Study of Respiratory Syncytial Virus–associated Deaths in Pediatric Patients in Canada, 2003–2013. Clinical Infectious Diseases, 2019, 68, 113-119.	2.9	26
22	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. Chest, 2019, 155, 69-78.	0.4	67
23	Motivation for participating in phase $1$ vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial. Vaccine, 2019, 37, 289-295.	1.7	11
24	Severe Respiratory Syncytial Virus Infection in Preterm Infants and Later Onset of Asthma. Pediatric Infectious Disease Journal, 2019, 38, 1121-1125.	1.1	8
25	Results from the Canadian Nosocomial Infection Surveillance Program for detection of carbapenemase-producing ⟨i⟩ Acinetobacter ⟨/i⟩ spp. in Canadian hospitals, 2010–16. Journal of Antimicrobial Chemotherapy, 2019, 74, 315-320.	1.3	16
26	Determining proton pump inhibitor prescription dispensing patterns and adherence to STOPP criteria for Nova Scotia Seniors Pharmacare Program beneficiaries. Canadian Journal of Clinical Pharmacology, 2019, 26, e37-e51.	1,1	4
27	A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. Journal of Infectious Diseases, 2018, 218, 378-387.	1.9	39
28	Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). Vaccine, 2018, 36, 2166-2175.	1.7	52
29	Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform. Human Vaccines and Immunotherapeutics, 2018, 14, 59-66.	1.4	4
30	A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response. Clinical Infectious Diseases, 2018, 67, 1063-1071.	2.9	84
31	Contact among healthcare workers in the hospital setting: developing the evidence base for innovative approaches to infection control. BMC Infectious Diseases, 2018, 18, 184.	1.3	18
32	Early Onset Invasive Candidiasis in Extremely Low Birth Weight Infants: Perinatal Acquisition Predicts Poor Outcome. Clinical Infectious Diseases, 2017, 64, cix001.	2.9	26
33	Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. Cmaj, 2017, 189, E819-E827.	0.9	67
34	Reply to Weber, von Cube, Sommer, Wolkewitz: Necessity of a Competing Risk Approach in Risk Factor Analysis of Central-Line–Associated Bloodstream Infection. Infection Control and Hospital Epidemiology, 2017, 38, 511-511.	1.0	2
35	Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during a meningococcal serogroup B outbreak vaccination program. Vaccine, 2017, 35, 2520-2530.	1.7	21
36	Risk factors for surgical site infection following cesarean delivery: a retrospective cohort study. CMAJ Open, 2017, 5, E546-E556.	1.1	18

#	Article	lF	CITATIONS
37	Assessing the risk of intussusception and rotavirus vaccine safety in Canada. Human Vaccines and Immunotherapeutics, 2017, 13, 703-710.	1.4	18
38	A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. Journal of Infectious Diseases, 2017, 215, 24-33.	1.9	58
39	Vaccine Prevention of Respiratory Syncytial Virus Infection in Older Adults: The Work Continues. Journal of Infectious Diseases, 2017, 216, 1334-1336.	1.9	4
40	2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clinical Infectious Diseases, 2017, 65, 1963-1973.	2.9	280
41	2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clinical Infectious Diseases, 2017, 65, e45-e80.	2.9	339
42	The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. Journal of Infectious Diseases, 2017, 216, 405-414.	1.9	133
43	An Integrated Needs-Based Approach to Health Service and Health Workforce Planning: Applications for Pandemic Influenza. Healthcare Policy, 2017, 13, 28-42.	0.3	8
44	Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS ONE, 2017, 12, e0175721.	1.1	14
45	Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. BMC Infectious Diseases, 2017, 17, 805.	1.3	21
46	Toward Standardizing a Lexicon of Infectious Disease Modeling Terms. Frontiers in Public Health, 2016, 4, 213.	1.3	19
47	Estimating Respiratory Syncytial Virus-associated Hospitalization in the First Year of Life Among Infants Born at 32–35 Weeks of Gestation. Pediatric Infectious Disease Journal, 2016, 35, 851-855.	1.1	5
48	Results from the Canadian Nosocomial Infection Surveillance Program on Carbapenemase-Producing <i>Enterobacteriaceae</i> , 2010 to 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 6787-6794.	1.4	55
49	The role of healthcare provider attitudes in increasing willingness to accept seasonal influenza vaccine policy changes. Vaccine, 2016, 34, 5704-5707.	1.7	3
50	Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study. Vaccine, 2016, 34, 4046-4049.	1.7	21
51	Risk Factors for Central Venous Catheter–Associated Bloodstream Infection in Pediatric Patients: A Cohort Study. Infection Control and Hospital Epidemiology, 2016, 37, 939-945.	1.0	38
52	Knowledge, attitudes, beliefs, and behaviors of pregnant women approached to participate in a Tdap maternal immunization randomized, controlled trial. Human Vaccines and Immunotherapeutics, 2016, 12, 879-885.	1.4	30
53	Routine immunization of adults by pharmacists: Attitudes and beliefs of the Canadian public and health care providers. Human Vaccines and Immunotherapeutics, 2016, 12, 623-631.	1.4	39
54	Economic evaluation of vaccines in Canada: A systematic review. Human Vaccines and Immunotherapeutics, 2016, 12, 1257-1264.	1.4	8

#	Article	IF	CITATIONS
55	Reducing infection transmission in the playroom: Balancing patient safety and family-centered care. American Journal of Infection Control, 2016, 44, 61-65.	1.1	8
56	Knowledge, attitudes, beliefs, and behaviors of parents and healthcare providers before and after implementation of a universal rotavirus vaccination program. Vaccine, 2016, 34, 687-695.	1.7	15
57	Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. Vaccine, 2015, 33, 6635-6640.	1.7	13
58	Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What the Canadian public knows and wants to know. Vaccine, 2015, 33, 6840-6848.	1.7	9
59	The challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers. BMJ Open, 2015, 5, e009062.	0.8	69
60	Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 242-251.	0.6	28
61	Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial. Vaccine, 2015, 33, 559-567.	1.7	14
62	Complete Sequence of Four Multidrug-Resistant MOB <sub>Q1</sub> Plasmids Harboring <i>bla</i> <sub>GES-5</sub> Isolated from <i>Escherichia coli</i> and <i>Serratia marcescens</i> Persisting in a Hospital in Canada. Microbial Drug Resistance, 2015, 21, 253-260.	0.9	15
63	Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What Canadian health care providers know and need to know. Human Vaccines and Immunotherapeutics, 2015, 11, 2167-2179.	1.4	16
64	Adolescent immunization - Protecting youth and preparing them for a healthy future. International Journal of Pediatrics and Adolescent Medicine, 2015, 2, 1-6.	0.5	4
65	Healthcare-Associated Clostridium difficile Infections and Strain Diversity in Pediatric Hospitals in the Canadian Nosocomial Infection Surveillance Program, 2007-2011. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e151-e154.	0.6	4
66	A universal infant rotavirus vaccine program in two delivery models: Effectiveness and adverse events following immunization. Human Vaccines and Immunotherapeutics, 2015, 11, 870-874.	1.4	7
67	Against vaccine assay secrecy. Human Vaccines and Immunotherapeutics, 2015, 11, 498-503.	1.4	1
68	Canadian vaccine research networks: Vaccine safety resources for Canada. Canada Communicable Disease Report, 2015, 41, 18-23.	0.6	4
69	Implementation of a universal rotavirus vaccination program: comparison of two delivery systems. BMC Public Health, 2014, 14, 908.	1.2	9
70	Incorporating economic evaluation into immunization decision making in Canada: a workshop. Expert Review of Vaccines, 2014, 13, 1291-1296.	2.0	4
71	Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age. Journal of the Pediatric Infectious Diseases Society. 2014. 3. 33-42.	0.6	22
72	Complete sequences of a novel blaNDM-1-harbouring plasmid from Providencia rettgeri and an FII-type plasmid from Klebsiella pneumoniae identified in Canada. Journal of Antimicrobial Chemotherapy, 2014, 69, 637-642.	1.3	42

#	Article	IF	CITATIONS
73	Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. BMC Infectious Diseases, 2014, 14, 327.	1.3	57
74	Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014. Eurosurveillance, 2014, 19, .	3.9	41
75	Severe Combined Immunodeficiency (SCID) in Canadian Children: A National Surveillance Study. Journal of Clinical Immunology, 2013, 33, 1310-1316.	2.0	26
76	Respiratory syncytial virus - associated intensive care unit admission in children in Southern China. BMC Research Notes, 2013, 6, 447.	0.6	15
77	Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children. Journal of Infectious Diseases, 2013, 208, 544-553.	1.9	62
78	Elevated Inflammatory Mediators in Adults with Oculorespiratory Syndrome following Influenza Immunization: a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study. Vaccine Journal, 2013, 20, 1108-1114.	3.2	10
79	Pilot-testing an applied competency-based approach to health human resources planning. Health Policy and Planning, 2013, 28, 739-749.	1.0	19
80	Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. Journal of Antimicrobial Chemotherapy, 2013, 68, 1505-1509.	1.3	51
81	Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women. JAMA - Journal of the American Medical Association, 2013, 309, 1793.	3.8	352
82	Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered) Tj ETQq0 licensed hepatitis B vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 1438-1444.	0 0 0 rgBT / 1.4	Overlock 10 1
83	Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6–35 Months: A Randomized, Controlled Trial. Journal of the Pediatric Infectious Diseases Society, 2012, 1, 55-63.	0.6	29
84	Human challenge studies: a review of adequacy of reporting methods and results. Future Microbiology, 2012, 7, 481-495.	1.0	19
85	The authors respond. Cmaj, 2012, 184, 1926.4-1927.	0.9	O
86	Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent menACWY conjugate vaccine formulations. Archives of Disease in Childhood, 2012, 97, A22.3-A22.	1.0	0
87	National Surveillance of Methicillin-resistant Staphylococcus aureus Among Hospitalized Pediatric Patients in Canadian Acute Care Facilities, 1995–2007. Pediatric Infectious Disease Journal, 2012, 31, 814-820.	1.1	15
88	Safety and Immunogenicity of 2 Mixed Primary Infant Immunization Schedules of Pentavalent Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis, and Haemophilus influenzae Type b Vaccines at 2, 4, and 6 Months of Age. Pediatric Infectious Disease Journal, 2012, 31, 189-192.	1.1	8
89	Randomized, Multicenter Trial of a Single Dose of AS03-adjuvanted or Unadjuvanted H1N1 2009 Pandemic Influenza Vaccine in Children 6 Months to <9 Years of Age. Pediatric Infectious Disease Journal, 2012, 31, 848-858.	1.1	13
90	A randomized control trial comparing immunogenicity, safety, and preference for self-versus nurse-administered intradermal influenza vaccine. Vaccine, 2012, 30, 6287-6293.	1.7	31

#	Article	IF	Citations
91	Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine, 2012, 30, 974-982.	1.7	47
92	Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age. Vaccine, 2012, 30, 2556-2563.	1.7	107
93	Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine, 2012, 30, 2831-2838.	1.7	29
94	Safety and immunogenicity of 2010–2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12–59 months of age previously given ASO3-adjuvanted H1N12009 pandemic vaccine: A PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine, 2012, 30, 3389-3394.	1.7	15
95	Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate) Tj ETQq1 1 0.784314	ngBT/Ov	ier <b>32</b> ck 10 Ti
96	A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without ASO3 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. BMC Infectious Diseases, 2012, 12, 279.	1.3	15
97	Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study. Journal of Infectious Diseases, 2011, 203, 1729-1738.	1.9	70
98	A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine, 2011, 29, 1921-1928.	1.7	28
99	Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of ASO3 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months. Vaccine, 2011, 29, 6408-6418.	1.7	15
100	Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4–5 years after a previous dose. Vaccine, 2011, 29, 8459-8465.	1.7	40
101	An Incremental Economic Evaluation of Targeted and Universal Influenza Vaccination in Pregnant Women. Canadian Journal of Public Health, 2011, 102, 445-450.	1.1	23
102	Health Care–Associated Infection in the Pediatric Intensive Care Unit. , 2011, , 1349-1363.		5
103	A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice. Canadian Respiratory Journal, 2011, 18, e10-e19.	0.8	68
104	The Geographic Synchrony of Seasonal Influenza: A Waves across Canada and the United States. PLoS ONE, 2011, 6, e21471.	1.1	23
105	Serratia marcescens outbreak in a neonatal intensive care unit related to the exit port of an oscillator. Pediatric Critical Care Medicine, 2011, 12, e282-e286.	0.2	16
106	Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children. Pediatric Infectious Disease Journal, 2011, 30, 402-407.	1,1	23
107	Strategies for successful rapid trials of influenza vaccine. Clinical Trials, 2011, 8, 699-704.	0.7	7
108	Kinetics of the Antibody Response to Tetanus-Diphtheria-Acellular Pertussis Vaccine in Women of Childbearing Age and Postpartum Women. Clinical Infectious Diseases, 2011, 53, 885-892.	2.9	139

#	Article	IF	CITATIONS
109	Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002. BMC Infectious Diseases, 2010, 10, 219.	1.3	48
110	Original Article: A composite epidemic curve for seasonal influenza in Canada with an international comparison. Influenza and Other Respiratory Viruses, 2010, 4, 295-306.	1.5	23
111	Safety and Crossâ€Reactive Immunogenicity of Candidate ASO3â€Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults. Journal of Infectious Diseases, 2010, 201, 1644-1653.	1.9	81
112	Canada's National Advisory Committee on Immunization (NACI): Evidence-based decision-making on vaccines and immunization. Vaccine, 2010, 28, A58-A63.	1.7	33
113	A global prescription for adult immunization: Time is catching up with us. Vaccine, 2010, 28, 7137-7139.	1.7	31
114	Hepatitis A and travel amongst Nova Scotia postsecondary students: Evidence for a targeted vs. universal immunization strategy. Vaccine, 2010, 28, 8105-8111.	1.7	7
115	Health-associated infections in a pediatric nephrology unit in China. American Journal of Infection Control, 2010, 38, 473-475.	1.1	5
116	Prospects for defined epitope vaccines for respiratory syncytial virus. Future Microbiology, 2010, 5, 585-602.	1.0	31
117	Respiratory Watch: Development of a Provincial System for Respiratory Syncytial Virus Surveillance in Nova Scotia, 2005–2008. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e153-e156.	0.7	0
118	In Memoriam, Bernard Duval (1949 – 2008). Hum Vaccin, 2009, 5, 770-772.	2.4	0
119	Improving the quality of care for infants: a cluster randomized controlled trial. Cmaj, 2009, 181, 469-476.	0.9	103
120	Characteristics and outcome of infants with candiduria in neonatal intensive care - a Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. BMC Infectious Diseases, 2009, 9, 183.	1.3	49
121	A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age. Vaccine, 2009, 27, 5913-5919.	1.7	53
122	Study of Cerebrospinal Fluid Shunt–Associated Infections in the First Year Following Placement, by the Canadian Nosocomial Infection Surveillance Program. Infection Control and Hospital Epidemiology, 2009, 30, 285-288.	1.0	17
123	Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants. Pediatric Infectious Disease Journal, 2009, 28, 186-193.	1.1	58
124	Estimating Sensitivity of Laboratory Testing for Influenza in Canada through Modelling. PLoS ONE, 2009, 4, e6681.	1.1	7
125	Empyema associated with community-acquired pneumonia: A Pediatric Investigator's Collaborative Network on Infections in Canada (PICNIC) study. BMC Infectious Diseases, 2008, 8, 129.	1.3	52
126	Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza and Other Respiratory Viruses, 2008, 2, 1-8.	1.5	70

#	Article	IF	Citations
127	Co-morbidities associated with influenza-attributed mortality, 1994–2000, Canada. Vaccine, 2008, 26, 4697-4703.	1.7	64
128	Development and Validation of a Risk Scoring Tool to Predict Respiratory Syncytial Virus Hospitalization in Premature Infants Born at 33 through 35 Completed Weeks of Gestation. Medical Decision Making, 2008, 28, 471-480.	1,2	71
129	Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants. JAMA - Journal of the American Medical Association, 2008, 299, 173-84.	3.8	194
130	Influenza: a multipronged approach to protecting our smallest patients. Medscape Journal of Medicine, 2008, 10, 261.	0.6	0
131	Health Care Epidemiology Perspective on the October 2006 Recommendations of the Subcommittee on Diagnosis and Management of Bronchiolitis. Pediatrics, 2007, 120, 890-892.	1.0	23
132	Release of the statement on influenza for the 2007 2008 season from the National Advisory Committee on Immunization. Cmaj, 2007, 177, 1025-1026.	0.9	3
133	Influenza and the influenza vaccine. Cmaj, 2007, 177, 1028-1028.	0.9	0
134	Influenza-Attributed Hospitalization Rates Among Pregnant Women in Canada 1994–2000. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 622-629.	0.3	103
135	Influenza-attributable deaths, Canada 1990–1999. Epidemiology and Infection, 2007, 135, 1109-1116.	1.0	98
136	Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine, 2007, 25, 450-457.	1.7	44
137	An adolescent–adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4–6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine, 2007, 25, 1121-1125.	1.7	31
138	Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine, 2007, 25, 3464-3474.	1.7	27
139	Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: A successful provincial respiratory syncytial virus prophylaxis program. Canadian Journal of Cardiology, 2007, 23, 463-466.	0.8	9
140	A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults. International Congress Series, 2006, 1289, 303-306.	0.2	19
141	Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine, 2006, 24, 20-26.	1.7	118
142	Safety and immunogenicity of a Proteosomeâ,,¢-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine, 2006, 24, 1601-1608.	1.7	35
143	Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15–20-month-old toddlers. Vaccine, 2006, 24, 4017-4023.	1.7	15
144	Modelling the Impact of Influenza in Canada: A Baseline for Pandemic Planning. American Journal of Epidemiology, 2006, 163, S193-S193.	1.6	3

#	Article	IF	CITATIONS
145	Hospitalization Attributable to Influenza and Other Viral Respiratory Illnesses in Canadian Children. Pediatric Infectious Disease Journal, 2006, 25, 795-800.	1.1	111
146	Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of aseptic meningitis. BMC Infectious Diseases, 2006, 6, 68.	1.3	50
147	Commentary on †Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts', with response from review author. Evidence-Based Child Health: A Cochrane Review Journal, 2006, 1, 1344-1346.	2.0	0
148	Highlights of the National Advisory Committee on Immunization statement on influenza for the 2006-2007 season. Cmaj, 2006, 175, 742-742.	0.9	2
149	Review: antiviral agents reduce the risk of influenza in healthy adults and alleviate symptoms faster than placebo. Evidence-Based Medicine, 2006, 11, 141-141.	0.6	0
150	No socomial Infections in the Pediatric Intensive Care Unit: Epidemiology and Control. , 2006, , 1394-1421.		5
151	Influenza update: NACI issues annual influenza prevention recommendations for the 2006/2007 season. Paediatrics and Child Health, 2006, 11, 391-2.	0.3	0
152	Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076]. BMC Pediatrics, 2005, 5, 7.	0.7	33
153	Adenoviruses. Pediatrics in Review, 2005, 26, 244-249.	0.2	25
154	Defining urinary tract infection in the critically ill child. Pediatric Critical Care Medicine, 2005, 6, S25-S29.	0.2	20
155	Defining pneumonia in critically ill infants and children. Pediatric Critical Care Medicine, 2005, 6, S9-S13.	0.2	52
156	Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers. Clinical Infectious Diseases, 2005, 41, 1114-1122.	2.9	271
157	Adenoviruses. Pediatrics in Review, 2005, 26, 244-249.	0.2	5
158	Prevention of influenza in the general population. Cmaj, 2004, 171, 1213-1222.	0.9	49
159	Prevention of influenza in the general population: recommendation statement from the Canadian Task Force on Preventive Health Care. Cmaj, 2004, 171, 1169-1170.	0.9	13
160	Azithromycin Is as Effective as and Better Tolerated Than Erythromycin Estolate for the Treatment of Pertussis. Pediatrics, 2004, 114, e96-e101.	1.0	106
161	The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation. Pediatric Infectious Disease Journal, 2004, 23, 806-814.	1.1	208
162	Coxiella burnetii seropositivity in parturient women is associated with adverse pregnancy outcomes. American Journal of Obstetrics and Gynecology, 2003, 189, 228-232.	0.7	70

#	Article	IF	CITATIONS
163	A pilot study to quantify parental anxiety associated with enrollment of an infant or toddler in a phase III vaccine trial. Vaccine, 2003, 21, 3863-3866.	1.7	5
164	Increasing Incidence of Hospitalization for Bronchiolitis among Canadian Children, 1980–2000. Journal of Infectious Diseases, 2003, 188, 1764-1767.	1.9	67
165	Commentary: Waterless hand hygiene&OV0093if there's a will, there's a way. Pediatric Infectious Disease Journal, 2002, 21, 496-497.	1.1	3
166	The Role of Clostridium difficile and Viruses as Causes of Nosocomial Diarrhea in Children. Infection Control and Hospital Epidemiology, 2002, 23, 660-664.	1.0	61
167	From Soap and Water, to Waterless Agents: Update on Hand Hygiene in Health Care Settings. Canadian Journal of Infectious Diseases & Medical Microbiology, 2002, 13, 285-286.	0.3	6
168	History of penicillin allergy and referral for skin testing: evaluation of a pediatric penicillin allergy testing program. Clinical and Investigative Medicine, 2002, 25, 181-4.	0.3	3
169	Unique epidemiology of nosocomial urinary tract infection in children. American Journal of Infection Control, 2001, 29, 94-98.	1.1	90
170	Interobserver variability of croup scoring in clinical practice. Paediatrics and Child Health, 2001, 6, 347-351.	0.3	19
171	PICNIC update. Paediatrics and Child Health, 2000, 5, 393-394.	0.3	0
172	Variation in risk for nosocomial chickenpox after inadvertent exposure. Journal of Hospital Infection, 2000, 44, 224-226.	1.4	19
173	Canadian Acute Respiratory Illness and Flu Scale (CARIFS). Journal of Clinical Epidemiology, 2000, 53, 793-799.	2.4	78
174	A Randomized, Placebo-Controlled Trial of Erythromycin Estolate Chemoprophylaxis for Household Contacts of Children With Culture-PositiveBordetella pertussisInfection. Pediatrics, 1999, 104, e42-e42.	1.0	60
175	Diagnosis?. Canadian Journal of Infectious Diseases & Medical Microbiology, 1999, 10, 336-365.	0.3	0
176	Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Infectious Disease Journal, 1999, 18, 866-869.	1.1	89
177	Seven Days of Erythromycin Estolate Is as Effective as Fourteen Days for the Treatment of Bordetella pertussis Infections. Pediatrics, 1997, 100, 65-71.	1.0	82
178	Economic evaluation of respiratory syncytial virus infection in Canadian children: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. Journal of Pediatrics, 1997, 131, 113-117.	0.9	103
179	Validation of croup scoring methods 694. Pediatric Research, 1997, 41, 118-118.	1.1	0
180	Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. Journal of Pediatrics, 1996, 129, 390-395.	0.9	213

#	Article	IF	CITATIONS
181	Study of interobserver reliability in clinical assessment of RSV lower respiratory illness: A pediatric investigators collaborative network for infections in Canada (PICNIC) study., 1996, 22, 23-27.		26
182	Immune Responses to Pertussis Vaccines Concurrently Administered with Viral Vaccines. Annals of the New York Academy of Sciences, 1995, 754, 89-96.	1.8	11
183	Efficacy of Antimicrobial Prophylaxis in Placement of Cerebrospinal Fluid Shunts: Meta-Analysis. Clinical Infectious Diseases, 1993, 17, 98-103.	2.9	145
184	Evaluation of a tuberculosis screening program at a children's hospital. American Journal of Infection Control, 1992, 20, 19-23.	1.1	6
185	Sepsis in febrile neutropenic children with cancer. Pediatric Infectious Disease Journal, 1988, 7, 34-36.	1.1	56
186	Poker Players' Pneumonia. New England Journal of Medicine, 1988, 319, 354-356.	13.9	142
187	Cerebrospinal fluid shunt–associated surgical site infection with three-month versus twelve-month surveillance periods in Canadian hospitals. Infection Control and Hospital Epidemiology, 0, , 1-4.	1.0	0